WO2000049007A8 - Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s - Google Patents

Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s

Info

Publication number
WO2000049007A8
WO2000049007A8 PCT/GB2000/000532 GB0000532W WO0049007A8 WO 2000049007 A8 WO2000049007 A8 WO 2000049007A8 GB 0000532 W GB0000532 W GB 0000532W WO 0049007 A8 WO0049007 A8 WO 0049007A8
Authority
WO
WIPO (PCT)
Prior art keywords
cathepsin
compound
formula
medicament
acetamido
Prior art date
Application number
PCT/GB2000/000532
Other languages
English (en)
Other versions
WO2000049007A1 (fr
Inventor
Howard Tucker
Michael Stewart Large
John Oldfield
Craig Johnstone
Philip Neil Edwards
Original Assignee
Astrazeneca Ab
Howard Tucker
Michael Stewart Large
John Oldfield
Craig Johnstone
Philip Neil Edwards
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903857.2A external-priority patent/GB9903857D0/en
Priority claimed from GBGB9916098.8A external-priority patent/GB9916098D0/en
Application filed by Astrazeneca Ab, Howard Tucker, Michael Stewart Large, John Oldfield, Craig Johnstone, Philip Neil Edwards filed Critical Astrazeneca Ab
Priority to JP2000599747A priority Critical patent/JP2002537293A/ja
Priority to EP00903848A priority patent/EP1155010A1/fr
Priority to AU25603/00A priority patent/AU2560300A/en
Publication of WO2000049007A1 publication Critical patent/WO2000049007A1/fr
Publication of WO2000049007A8 publication Critical patent/WO2000049007A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

L'invention concerne un composé correspondant à la formule (I) dans laquelle Ar, R?1, R2, R3, R4 et R5¿ possèdent les notations données dans la description. Elle concerne également une composition comprenant un composé correspondant à la formule (I) ainsi qu'un excipient ou diluant; elle concerne encore l'emploi d'un composé correspondant à la formule (I) à dans la fabrication d'un médicament utile pour inhiber une cystéine protéase chez un animal de sang chaud, l'emploi d'un tel composé dans la fabrication d'un médicament utile dans le traitement du syndrome respiratoire obstructif chronique, chez un animal de sang chaud, ainsi qu'un procédé de traitement d'une pathologie induite par la cathepsine L ou S, consistant à administrer à un mammifère nécessitant un tel traitement une dose efficace d'un composé correspondant à la formule (I).
PCT/GB2000/000532 1999-02-20 2000-02-16 Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s WO2000049007A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000599747A JP2002537293A (ja) 1999-02-20 2000-02-16 カテプシンｌおよび／またはカテプシンｓの阻害剤としてのアセタミドアセトニトリル誘導体
EP00903848A EP1155010A1 (fr) 1999-02-20 2000-02-16 Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s
AU25603/00A AU2560300A (en) 1999-02-20 2000-02-16 Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9903857.2A GB9903857D0 (en) 1999-02-20 1999-02-20 Chemical compounds
GB9916098.8 1999-07-10
GBGB9916098.8A GB9916098D0 (en) 1999-07-10 1999-07-10 Chemical compounds
GB9903857.2 1999-07-10

Publications (2)

Publication Number Publication Date
WO2000049007A1 WO2000049007A1 (fr) 2000-08-24
WO2000049007A8 true WO2000049007A8 (fr) 2001-03-15

Family

ID=26315158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000532 WO2000049007A1 (fr) 1999-02-20 2000-02-16 Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s

Country Status (4)

Country Link
EP (1) EP1155010A1 (fr)
JP (1) JP2002537293A (fr)
AU (1) AU2560300A (fr)
WO (1) WO2000049007A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051998A1 (fr) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
SI1178958T1 (en) * 1999-03-15 2004-08-31 Axys Pharmaceuticals, Inc. N-cyanomethyl amides as protease inhibitors
IL145430A0 (en) 1999-03-15 2002-06-30 Axys Pharm Inc N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
CA2396257A1 (fr) * 2000-01-06 2001-07-12 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Nouveaux composes et compositions utilises comme inhibiteurs de protease
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
CA2407463C (fr) * 2000-05-15 2010-01-12 Scott Douglas Cowen Utilisation de peptidyl nitriles a substitution- n comme inhibiteurs des cathepsines de cysteine
US6812237B2 (en) 2000-05-15 2004-11-02 Novartis Ag N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
WO2002050052A1 (fr) * 2000-12-20 2002-06-27 Syngenta Participations Ag N-acyl aminoacetonitriles aux proprietes pesticides
WO2002051983A2 (fr) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Composes et compositions en tant qu'inhibiteurs de cathepsine
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
EP1372655B1 (fr) 2001-03-02 2008-10-01 Merck Frosst Canada Ltd. Inhibiteurs de cathepsines de la cysteine protease
US6982263B2 (en) 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
WO2003024924A1 (fr) 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Nouveaux composes et nouvelles compositions utiles comme inhibiteurs de la cathepsine
MXPA04004450A (es) 2001-11-14 2004-08-11 Aventis Pharma Inc Nuevos compuestos y composiciones como inhibidores de catepsina s.
PT1482924E (pt) 2002-03-05 2008-08-27 Axys Pharm Inc Inibidores de proteases da cisteína catepsina
WO2003086325A2 (fr) * 2002-04-05 2003-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides utiles en tant qu'inhibiteurs reversibles des cysteine proteases
US6878706B1 (en) 2002-04-05 2005-04-12 Boehringer Ingelheim Pharmaceuticals Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
US7279478B2 (en) 2002-09-04 2007-10-09 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
TWI376363B (en) 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
US7326719B2 (en) 2003-03-13 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
US7465745B2 (en) 2003-03-13 2008-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
WO2004089395A2 (fr) * 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Utilisation d'un inhibiteur de la cathepsine-s ou -b afin de traiter ou de prevenir les maladies pulmonaires obstructives chroniques
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
MX2007003118A (es) * 2004-09-17 2007-05-24 Schering Ag Procedimiento de intermediarios para preparar inhibidores de cisteina proteasa.
EP1891003A4 (fr) * 2005-06-02 2010-07-21 Merck Frosst Canada Ltd Derives de fluoroalkylamine utilises comme inhibiteurs de la cathepsine
WO2007017088A1 (fr) * 2005-07-25 2007-02-15 Novartis Ag Composés amidonitrile
EP2240491B1 (fr) 2008-01-09 2015-07-15 Amura Therapeutics Limited DÉRIVÉS DE TÉTRAHYDROFURO(2,3-b)PYRROL-3-ONE COMME INHIBITEURS DE CYSTÉINE PROTÉINASES
KR20180017232A (ko) 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
EP2198879A1 (fr) 2008-12-11 2010-06-23 Institut Curie Agent modulateur de CD74 pour la régulation de la migration de cellules dendritiques et dispositif pour l'étude de la capacité de motilité d'une cellule
MX2015005711A (es) 2012-11-14 2015-08-20 Hoffmann La Roche Nuevos derivados de acetamida como antagonistas del canal receptor de potencial transitorio.
PL3043791T3 (pl) * 2013-09-13 2019-08-30 Pitney Pharmaceuticals Pty Limited Środek przeciwnowotworowy zawierający związek aminoacetonitrylowy jako substancję czynną
CN115466225A (zh) * 2022-08-16 2022-12-13 中国科学院上海药物研究所 一种酰胺类化合物及其制备方法、药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2846127A1 (de) * 1978-10-23 1980-04-30 Basf Ag 1,2,4-triazol-1-yl-verbindungen, ihre hersttellung und verwendung als fungizide
FR2446812A1 (fr) * 1979-01-16 1980-08-14 Produits Ind Cie Fse Phenoxy- et thiophenoxynitriles et leurs applications en tant qu'herbicides
US4567267A (en) * 1981-06-15 1986-01-28 American Home Products Corporation α-Phenyl-2-(aza)benzothiazolylthioglycolic acids and derivatives thereof
ES2043625T3 (es) * 1986-08-29 1994-01-01 Shell Int Research Derivados de acido ariloxicarboxilico, su preparacion y empleo.
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
JPH03218347A (ja) * 1989-11-10 1991-09-25 Nippon Soda Co Ltd カルボン酸アミド誘導体及びその製造方法
JPH05286937A (ja) * 1992-04-10 1993-11-02 Mitsubishi Petrochem Co Ltd 置換ピリジルオキシカルボン酸アミド誘導体およびそれを含有する農業用殺菌剤
JPH06211766A (ja) * 1993-01-18 1994-08-02 Mitsubishi Petrochem Co Ltd アルコキシカルボン酸アミド誘導体およびそれを含有する農業用殺菌剤
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
KR100511339B1 (ko) * 1996-10-31 2005-08-31 구미아이 가가쿠 고교 가부시키가이샤 피리미디닐옥시알카노산아미드 유도체 및 농원예용 살균제
US5942640A (en) * 1998-04-20 1999-08-24 American Cyanamid Company Process for the manufacture of N-(1-cyanoalkyl)-2-phenoxypropionamide derivatives

Also Published As

Publication number Publication date
WO2000049007A1 (fr) 2000-08-24
EP1155010A1 (fr) 2001-11-21
JP2002537293A (ja) 2002-11-05
AU2560300A (en) 2000-09-04

Similar Documents

Publication Publication Date Title
WO2000049007A8 (fr) Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
AU3664401A (en) Platelet adp receptor inhibitors
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
WO2005063745A8 (fr) Nouveaux composes de spiroindoline ou de spiroisoquinoline, methodes d'utilisation et compositions associees
WO2003044015A3 (fr) Acides heteroarylalkanoiques substitues
WO2004094384A3 (fr) Benzamide 2-hydroxy-3-diaminoalcanes
WO2002085909A8 (fr) Derives de 9-deazaguanine utilises comme inhibiteurs de la gsk-3
WO2005007681A3 (fr) Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
WO2001078711A3 (fr) Utilisation d'inhibiteurs de phosphodiesterase specifique de gmp cyclique pour le traitement de la maladie de parkinson
WO2001081312A3 (fr) Methode de traitement se basant sur l'utilisation de derives de phenyle et de biaryle comme inhibiteurs de prostaglandine e
CA2427227A1 (fr) Compose de lactam
WO2001072728A3 (fr) Nouveaux derives de piperazine
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
EP2039687A4 (fr) Agent thérapeutique ou prophylactique pour la sclérose en plaques
MXPA04003245A (es) Hidroxipropilaminas.
CA2283399A1 (fr) Pyridazinones utilises comme inhibiteurs de cyclo-oxygenase-2
CA2301742A1 (fr) Pyridines 2,3,5-trisubstituees utilisees comme inhibiteurs de la cyclo-oxygenase 2
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2003049690A3 (fr) Inhibiteurs de l'integrase du vih
WO2001091738A3 (fr) Inhibiteurs naaladase utilises pour traiter la sclerose laterale amyotrophique
WO2003053971A8 (fr) Antiviraux a base de pyridoquinoxaline
NZ516290A (en) Substituted phenoxyacetic acids
WO2003006443A3 (fr) Derives d'acide carboxylique, medicaments contenant ces composes, leur utilisation et leur production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 34/2000 UNDER (51) AFTER "C07D277:00" INSERT "C07D235:00"

WWE Wipo information: entry into national phase

Ref document number: 2000903848

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 599747

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09913769

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000903848

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000903848

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)